CANY
SANA icon

Caxton Associates (New York)’s Sana Biotechnology SANA Stock Holding History

Caxton Associates (New York)’s Portfolio SANA Stock Details SANA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-15,639
Closed -$51.1K – 630
2023
Q1 		$51.1K Buy
+15,639
New +$62.5K 0.01% 475

Other funds holding SANA

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $181B AUM 41.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Public Sector Pension Investment Board (PSP Investments)
Public Sector Pension Investment Board (PSP Investments) Montreal, Quebec, Canada $38.7B AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return

Caxton Associates (New York)'s SANA Position: Q2 2023 in Review

Caxton Associates (New York) sold out of Sana Biotechnology (SANA) in Q2 2023, closing a stake of 15,639 shares — an estimated $51.1K sold.

Caxton Associates (New York) first reported a position in SANA in Q1 2023 and held it in 1 quarter. The position peaked at $51.1K in Q1 2023. 123 funds tracked by Wall St. Rank hold SANA as of Q2 2023.

  • Caxton Associates (New York) reported no remaining Sana Biotechnology position as of Q2 2023 after selling out during the quarter.
  • Caxton Associates (New York) sold 15,639 Sana Biotechnology shares in Q2 2023, an estimated $51.1K.
  • Caxton Associates (New York) first reported a position in Sana Biotechnology in Q1 2023 and held it in 1 quarter.
  • Caxton Associates (New York)'s Sana Biotechnology position peaked at $51.1K in Q1 2023.
  • 123 funds tracked by Wall St. Rank held Sana Biotechnology as of Q2 2023.

Based on Caxton Associates (New York)'s 13F filing for Q2 2023, filed 15 Aug 2023.